Concepedia

B. Escudier

BE

Statistics

Publications

12

Citations

330

H-Index

10

Active since

1995

Affiliations

Institut Gustave Roussy(Current)

Memorial Sloan Kettering Cancer Center

Beth Israel Deaconess Medical Center

B. Escudier is an author at Institut Gustave Roussy specializing in oncology, medicine, and renal cell carcinoma.

Publications per year

1995–2017

12

Publications

12

Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe.

Sylvie Négrier, J Maral, M Drevon et al. · PubMed · 2000 · 61 citations

Medicine, Immunology, Oncology +16

A phase II study of dovitinib (TKI258), an FGFR- and VEGFR-inhibitor, in patients with advanced or metastatic renal cell cancer (mRCC).

Eric Angevin, Viktor Grünwald, Alain Ravaud et al. · Journal of Clinical Oncology · 2011 · 56 citations

Medicine, Oncology, Pharmacology +14

Can the combination of temsirolimus and bevacizumab improve the treatment of metastatic renal cell carcinoma (mRCC)? Results of the randomized TORAVA phase II trial.

B. Escudier, Sylvie Négrier, Gwénaëlle Gravis et al. · Journal of Clinical Oncology · 2010 · 52 citations

Medicine, Oncology, Pharmacology +15

Update on AVOREN trial in metastatic renal cell carcinoma (mRCC): Efficacy and safety in subgroups of patients (pts) and pharmacokinetic (PK) analysis

B. Escudier, Alain Ravaud, Sylvie Négrier et al. · Journal of Clinical Oncology · 2008 · 43 citations

Medicine, Oncology, Pharmacotherapy +17

A phase I/II study of dovitinib (TKI258), a FGFR and VEGFR inhibitor, in patients (pts) with advanced or metastatic renal cell cancer: Phase I results.

Eric Angevin, Chieh‐Yu Lin, A. U. Pande et al. · Journal of Clinical Oncology · 2010 · 23 citations

Medicine, Oncology, Pharmacology +15

1–5 of 12